Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703129 | 0.84 | LMNA (0.46) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL2698628 | 0.80 | PTPRC (0.45) | KMT2AALDH1A1LMNAPTPRCSMN1; SMN2 | |
| SCHEMBL18580627 | 0.75 | ALDH1A1 (0.40) | KMT2AMAPTALDH1A1 | |
| SCHEMBL7822262 | 0.73 | LMNA (0.58) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL1608761 | 0.72 | ALDH1A1 (0.40) | ALDH1A1HPGDCYP2C19 | |
| SCHEMBL6698447 | 0.72 | ERN1 (0.33) | — | |
| SCHEMBL17744625 | 0.70 | ALDH1A1 (0.41) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL6928480 | 0.69 | MAPT (0.56) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL557225 | 0.69 | MEN1 (0.38) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL77037 | 0.69 | TSHR (0.44) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | TRIGEN LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2002057273-A9 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LTD (GB) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002057273-A1 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | SERPINB1, SPINT2, CTRL | MEN1 2436/4885KMT2A 3131/4885MAPT 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.